Arch Biopartners Inc (ARCH) - Net Assets
Based on the latest financial reports, Arch Biopartners Inc (ARCH) has net assets worth CA$-3.88 Million CAD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$104.53K) and total liabilities (CA$3.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-3.88 Million |
| % of Total Assets | -3713.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 403.9 |
Arch Biopartners Inc - Net Assets Trend (1997–2025)
This chart illustrates how Arch Biopartners Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arch Biopartners Inc (1997–2025)
The table below shows the annual net assets of Arch Biopartners Inc from 1997 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | CA$-3.88 Million | +10.72% |
| 2024-09-30 | CA$-4.35 Million | +21.09% |
| 2023-09-30 | CA$-5.51 Million | -23.25% |
| 2022-09-30 | CA$-4.47 Million | -15.15% |
| 2021-09-30 | CA$-3.88 Million | -0.37% |
| 2020-09-30 | CA$-3.87 Million | -33.30% |
| 2019-09-30 | CA$-2.90 Million | -177.47% |
| 2018-09-30 | CA$-1.05 Million | -85.62% |
| 2017-09-30 | CA$-563.41K | -119.30% |
| 2016-09-30 | CA$-256.91K | -281.59% |
| 2015-09-30 | CA$141.48K | +2248.52% |
| 2014-09-30 | CA$-6.58K | +98.45% |
| 2013-09-30 | CA$-425.37K | -19.68% |
| 2012-09-30 | CA$-355.42K | -103.12% |
| 2011-09-30 | CA$-174.98K | -206.13% |
| 2010-09-30 | CA$164.87K | +147.66% |
| 2009-09-30 | CA$-345.96K | +80.51% |
| 2008-09-30 | CA$-1.77 Million | -75.18% |
| 2007-09-30 | CA$-1.01 Million | -57.24% |
| 2006-09-30 | CA$-644.38K | +27.37% |
| 2005-09-30 | CA$-887.26K | -38.79% |
| 2004-09-30 | CA$-639.29K | -974.49% |
| 2003-09-30 | CA$73.10K | +327.58% |
| 2002-09-30 | CA$17.10K | +110.72% |
| 2001-09-30 | CA$-159.43K | -107.80% |
| 2000-09-30 | CA$2.05 Million | +93.01% |
| 1999-09-30 | CA$1.06 Million | +923.02% |
| 1998-09-30 | CA$-128.74K | -479.51% |
| 1997-09-30 | CA$-22.22K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arch Biopartners Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3022231100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$29.64 Million | % |
| Total Equity | CA$-3.88 Million | 100.00% |
Arch Biopartners Inc Competitors by Market Cap
The table below lists competitors of Arch Biopartners Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SUSTAINABLE POWER CL.A
F:9QE
|
$22.08 Million |
|
CLPS INC. DL-0001
F:1UK
|
$22.08 Million |
|
B&M European Value Retail SA
LSE:BME
|
$22.08 Million |
|
THEWORKS.CO.UK PLC LS-01
F:6EU
|
$22.09 Million |
|
Lleidanetworks Serveis Telematics SA
MC:LLN
|
$22.06 Million |
|
Konsortium Transnasional Bhd
KLSE:4847
|
$22.05 Million |
|
Isofol Medical AB
ST:ISOFOL
|
$22.05 Million |
|
Japan Gold Corp
V:JG
|
$22.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arch Biopartners Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -4,347,697 to -3,881,536, a change of 466,161.
- Net loss of 1,552,744 reduced equity.
- New share issuances of 1,245,497 increased equity.
- Other factors increased equity by 773,408.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-1.55 Million | -40.0% |
| Share Issuances | CA$1.25 Million | +32.09% |
| Other Changes | CA$773.41K | +19.93% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Arch Biopartners Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-09-30 | CA$-0.01 | CA$0.46 | x |
| 1998-09-30 | CA$-0.03 | CA$0.46 | x |
| 1999-09-30 | CA$0.33 | CA$0.46 | x |
| 2000-09-30 | CA$0.64 | CA$0.46 | x |
| 2001-09-30 | CA$-0.03 | CA$0.46 | x |
| 2002-09-30 | CA$0.00 | CA$0.46 | x |
| 2003-09-30 | CA$0.00 | CA$0.46 | x |
| 2004-09-30 | CA$-0.01 | CA$0.46 | x |
| 2005-09-30 | CA$-0.02 | CA$0.46 | x |
| 2006-09-30 | CA$-0.02 | CA$0.46 | x |
| 2007-09-30 | CA$-0.04 | CA$0.46 | x |
| 2008-09-30 | CA$-0.06 | CA$0.46 | x |
| 2009-09-30 | CA$-0.01 | CA$0.46 | x |
| 2010-09-30 | CA$0.00 | CA$0.46 | x |
| 2011-09-30 | CA$0.00 | CA$0.46 | x |
| 2012-09-30 | CA$-0.01 | CA$0.46 | x |
| 2013-09-30 | CA$-0.01 | CA$0.46 | x |
| 2014-09-30 | CA$0.00 | CA$0.46 | x |
| 2015-09-30 | CA$0.00 | CA$0.46 | x |
| 2016-09-30 | CA$0.00 | CA$0.46 | x |
| 2017-09-30 | CA$-0.01 | CA$0.46 | x |
| 2018-09-30 | CA$-0.02 | CA$0.46 | x |
| 2019-09-30 | CA$-0.05 | CA$0.46 | x |
| 2020-09-30 | CA$-0.06 | CA$0.46 | x |
| 2021-09-30 | CA$-0.06 | CA$0.46 | x |
| 2022-09-30 | CA$-0.07 | CA$0.46 | x |
| 2023-09-30 | CA$-0.09 | CA$0.46 | x |
| 2024-09-30 | CA$-0.07 | CA$0.46 | x |
| 2025-09-30 | CA$-0.06 | CA$0.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arch Biopartners Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-261.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 0.00% | -29099.87% | 0.03x | 0.00x | CA$-2.65 Million |
| 1998 | 0.00% | -763.54% | 0.53x | 0.00x | CA$-750.66K |
| 1999 | -79.15% | -1684.33% | 0.04x | 1.19x | CA$-944.62K |
| 2000 | -52.03% | -304.51% | 0.15x | 1.16x | CA$-1.27 Million |
| 2001 | 0.00% | -140683.46% | 0.02x | 0.00x | CA$-2.38 Million |
| 2002 | -1780.31% | -20051.38% | 0.03x | 3.46x | CA$-306.09K |
| 2003 | -710.36% | -18.16% | 1.75x | 22.41x | CA$-526.61K |
| 2004 | 0.00% | -47.70% | 1.95x | 0.00x | CA$-1.21 Million |
| 2005 | 0.00% | -19.35% | 1.65x | 0.00x | CA$-280.25K |
| 2006 | 0.00% | -1.14% | 1.67x | 0.00x | CA$46.22K |
| 2007 | 0.00% | -22.01% | 1.71x | 0.00x | CA$-260.15K |
| 2008 | 0.00% | -17.98% | 4.59x | 0.00x | CA$-480.02K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-4.62 Million |
| 2010 | -4374.37% | 0.00% | 0.00x | 3.25x | CA$-7.23 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-428.77K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-293.78K |
| 2013 | 0.00% | -503.99% | 1.02x | 0.00x | CA$-147.41K |
| 2014 | 0.00% | -779.48% | 0.13x | 0.00x | CA$-397.85K |
| 2015 | -593.02% | -2228.96% | 0.06x | 4.59x | CA$-853.15K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-980.88K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.85 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-3.09 Million |
| 2019 | 0.00% | -2511.41% | 0.17x | 0.00x | CA$-2.07 Million |
| 2020 | 0.00% | -6818.28% | 0.09x | 0.00x | CA$-4.24 Million |
| 2021 | 0.00% | -30.10% | 1.46x | 0.00x | CA$-781.47K |
| 2022 | 0.00% | -144.02% | 1.55x | 0.00x | CA$-942.31K |
| 2023 | 0.00% | -167.71% | 1.69x | 0.00x | CA$-2.78 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-3.49 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.16 Million |
Industry Comparison
This section compares Arch Biopartners Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-1,068,462
- Average return on equity (ROE) among peers: 7.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arch Biopartners Inc (ARCH) | CA$-3.88 Million | 0.00% | N/A | $22.08 Million |
| Appili Therapeutics Inc (APLI) | $-10.92 Million | 0.00% | 0.00x | $1.39 Million |
| Aptose Biosciences Inc (APS) | $-4.54 Million | 0.00% | 0.00x | $4.38 Million |
| Devonian Health Group Inc (GSD) | $5.19 Million | 111.16% | 1.26x | $20.03 Million |
| Helix BioPharma Corp. (HBP) | $-17.00K | 0.00% | 0.00x | $109.95 Million |
| Hemostemix Inc (HEM) | $-7.37 Million | 0.00% | 0.00x | $9.54 Million |
| Universal Ibogaine Inc (IBO) | $197.12K | -49.77% | 0.10x | $1.13 Million |
| Innovotech Inc (IOT) | $-1.00 Million | 0.00% | 0.00x | $7.15 Million |
| Kane Biotech Inc (KNE) | $-984.84K | 0.00% | 0.00x | $3.63 Million |
| Microbix Biosystems Inc. (MBX) | $9.84 Million | 1.72% | 0.83x | $24.10 Million |
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more